<?xml version="1.0" encoding="UTF-8"?>
<p id="para0021">A search for inhibitors with broad antirespiratory RNA virus activity yielded the ribonucleoside analog 
 <italic>N</italic>
 <sup>4</sup>-hydroxycytidine (NHC), which showed oral efficacy against RSV and both highly-pathogenic avian and seasonal influenza viruses in mouse models.
 <xref rid="bib0090" ref-type="bibr">
  <sup>90</sup>
 </xref> Mechanistic characterization revealed that the compound is efficiently anabolized to the bioactive tri-phosphate form in ex vivo primary human airway epithelium cultures and in animal tissues, followed by incorporation as cytidine into viral RNA by influenza virus polymerases.
 <xref rid="bib0090" ref-type="bibr">
  <sup>90</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib0106" ref-type="bibr">
  <sup>106</sup>
 </xref> Tautomeric interconversions then cause base-pairing of the incorporated analog either as cytosine or uracil, resulting in high-frequency random C-to-U and G-to-A transition mutations in viral RNA replication or transcription products and thus inhibition through error catastrophe.
 <xref rid="bib0106" ref-type="bibr">
  <sup>106</sup>
 </xref> Additional studies have expanded the antiviral target spectrum of NHC to viruses of the flavivirus, alphavirus, coronavirus, and togavirus families,
 <xref rid="bib0107" ref-type="bibr">107</xref>, 
 <xref rid="bib0108" ref-type="bibr">108</xref>, 
 <xref rid="bib0109" ref-type="bibr">109</xref>, 
 <xref rid="bib0110" ref-type="bibr">110</xref>, 
 <xref rid="bib0111" ref-type="bibr">111</xref> demonstrating broad anti-RNA virus activity.
</p>
